Navigation Links
AssureRx Health Expands Management Team to Support Increasing Business Growth
Date:12/11/2012

MASON, Ohio, Dec. 11, 2012 /PRNewswire/ -- AssureRx Health, Inc. today announced four key additions to its leadership team. The management appointments coincide with the need to support increasing GeneSightRx pharmacogenomic testing services, which support healthcare providers in medication selection and the managing of side effects for patients with neuropsychiatric and other disorders.

"We continue to experience rapid adoption of our pharmacogenomic treatment support products that assist clinicians in selecting medications for patients with neuropsychiatric disorders. The additional management appointments enhance our capabilities in pharmacogenomic clinical trial development, new product development, pharmaceutical industry services, high throughput laboratory test operations, market development, and clinician education," said James S. Burns, president and CEO of AssureRx Health. "Our goal is to build the leading personalized medicine company offering pharmacogenomic treatment decision support solutions for neuropsychiatric, pain, ADHD, and other disorders."

Bryan M. Dechairo, PhD, Senior Vice President, Medical Affairs & Strategic Alliances, is responsible for clinical development of current and future products, as well as alliances with academic, pharmaceutical, and genomic partnerships. Bryan was previously head of Extramural Research and Development at Medco Research Institute, responsible for translating pharmacogenomics into medical and pharmacy practice innovations to improve Medco member health outcomes, as well as business development and strategic alliances impacting Medco's research through to commercial products. Prior to joining Medco, Bryan led a multi-disciplinary team of scientists and clinicians to deliver novel biomarkers for drug development as Neuroscience Lead and Director of Molecular Medicine at Pfizer Global Research and Development. He also held drug target discovery or diagnostic development positions at Oxagen, Sequana Therapeutics, and Roche Molecular Systems. Bryan received a PhD in complex human genetics from the Institute of Childs Health at the University College of London.

Stephen E. King, Vice President, Marketing, is responsible for overall AssureRx Health marketing efforts to increase awareness and adoption of the GeneSightRx product line, as well as corporate communications and advocacy relations. Stephen brings more than 20 years of pharmaceutical/biotech commercial expertise to AssureRx Health, with the vast majority dedicated to the CNS/neuroscience therapeutic area. Most recently, he served as Vice President of Commercial Operations at Alkermes, where he led all marketing and sales activities for the portfolio of products. His prior experience has also included the launch of several blockbuster pharmaceutical brands including Paxil and Effexor XR during his tenure with SmithKline Beecham Pharmaceuticals and Wyeth, respectively. Stephen has directed multiple new product launches in both domestic and international markets, and brings to AssureRx Health broad therapeutic area expertise including experience in CNS/neurosciences, pain, addiction, women's health, and endocrinology.

Rao V. Mulpuri, PhD, MBA, Vice President, Laboratory Operations, is responsible for all AssureRx Health multi-site commercial laboratory testing. Rao previously served as Director, Scientific Operations at the Catholic Health Initiatives Center for Translational Research (CHIC), responsible for establishing operational, informatics, IT, quality and regulatory strategies, development and implementation of molecular diagnostic tests (LDTs), and IT systems for electronic health records and genomic data. At Beckman Coulter Genomics, Rao was responsible for managing a CLIA-certified, cGMP/GLP compliant molecular genomics, biobanking and biologics testing facility. His experience also includes operating management positions at Cogenics/Clinical Data, Icoria/Cogenics, and Paradigm Genetics/Icoria. Rao received a PhD in physiology and biochemistry from Vikram University and an MBA from the University of North Carolina.

Scott M. Roth, Vice President, Product Development, has been promoted to lead the AssureRx Health Product Development team in building and supporting AssureRx Health treatment decision product offerings and the AssureRx Health LIMS system. Scott has been responsible for leading development of both AssureRx Health platform software architecture and commercial product software. Scott has extensive prior experience in software product development covering military defense, airline ticketing, credit card, and other applications. Previously, Scott served as Software Development Manager at Domin-8 Enterprise Solutions, managing and leading a team of software developers building property management Microsoft Windows and web based applications. At Spotlight Solutions, Scott was responsible for design and development of the corporate portal and software products.  At Attachmate Corporation, Scott was involved in developing some of the first commercially available e-commerce and e-banking web applications, and custom software applications for the United States Air Force and United Airlines. 

About AssureRx Health

AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping physicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Cincinnati Children's Hospital Medical Center and Mayo Clinic are equity holders and technology collaborators.

About GeneSightRx
GeneSightRx is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSightRx report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, FDA approved manufacturer's drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience and other factors can help a physician make personalized drug treatment choices for each patient.

Contact:
Stephen E. King
Vice President, Marketing
AssureRx Health, Inc.
(513) 234-0510
e-mail: sking@assurerxhealth.com

 


'/>"/>
SOURCE AssureRx Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AssureRx Health Raises $12.5 Million Series C Financing
2. AssureRx Health Launches Personalized Medicine Test for ADHD
3. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
4. Thoratec Presentation At Oppenheimer 23rd Annual Healthcare Conference To Be Webcast
5. STATEMENT OF CHAIRMAN AND CEO GEORGE BARRETT FORTUNE 21 CARDINAL HEALTH REGARDING FISCAL CLIFF
6. inVentiv Health Strengthens Clinical Leadership Team
7. USANA True Health Foundation: Musician Donates Proceeds Of Holiday Song To Charity
8. Henry Schein To Present At The Oppenheimer 23rd Annual Healthcare Conference
9. Health Outcomes Liaisons Key to Pharmaceutical Sector Navigating Payer-Focused Marketplace
10. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
11. The First Lean Healthcare App is Now Available in Apples App Store
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... YORK , April 19, 2017 Cardiology devices ... the projected period The Cardiology Devices segment is ... than US$ 15 Mn in 2018 over 2017. By the ... a market valuation close to US$ 700 Mn, expanding at ... Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Miami native and local periodontist Dr. John ... have never imagined back in 1991 that this journey would have taken me into ... last 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally ...
(Date:4/26/2017)... ... April 26, 2017 , ... New SUPRO® XT55 ... high-protein beverages by helping beverage manufacturers more effectively manage protein costs. “Soy protein ... savings as well as more stable pricing over time. Now it’s even more ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... topical cream that’s the first in a new class of photodynamic cosmetics (PDC). ... appearance of skin, visibly reduce outward signs of aging, and minimize the appearance ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... Liberty attempts to compare student test score performance for the 2015-16 school year ... the state’s voucher programs. Though it highlights important patterns in student test score ...
Breaking Medicine News(10 mins):